These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24807674)

  • 1. Downregulation of galectin-3 causes a decrease in uPAR levels and inhibits the proliferation, migration and invasion of hepatocellular carcinoma cells.
    Zheng D; Hu Z; He F; Gao C; Xu L; Zou H; Wu Z; Jiang X; Wang J
    Oncol Rep; 2014 Jul; 32(1):411-8. PubMed ID: 24807674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells.
    Bessard A; Frémin C; Ezan F; Coutant A; Baffet G
    J Cell Physiol; 2007 Aug; 212(2):526-36. PubMed ID: 17427199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A; Xue M; Jackson C; Smith RC
    Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
    Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
    J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of Notch1 inhibits the invasion of human hepatocellular carcinoma HepG2 and MHCC97H cells through the regulation of PTEN and FAK.
    Hu YJ; Li HY; Qiu KJ; Li DC; Zhou JH; Hu YH; Zhang FM
    Int J Mol Med; 2014 Oct; 34(4):1081-6. PubMed ID: 25110169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells.
    Yuan S; Lei S; Wu S
    Oncol Rep; 2013 Oct; 30(4):1715-22. PubMed ID: 23912592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration.
    Chiu CY; Kuo KK; Kuo TL; Lee KT; Cheng KH
    Mol Cancer Res; 2012 Mar; 10(3):415-27. PubMed ID: 22241220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EFEMP1 inhibits migration of hepatocellular carcinoma by regulating MMP2 and MMP9 via ERK1/2 activity.
    Dou CY; Cao CJ; Wang Z; Zhang RH; Huang LL; Lian JY; Xie WL; Wang LT
    Oncol Rep; 2016 Jun; 35(6):3489-95. PubMed ID: 27108677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MECP2 promotes cell proliferation by activating ERK1/2 and inhibiting p38 activity in human hepatocellular carcinoma HEPG2 cells.
    Zhao LY; Zhang J; Guo B; Yang J; Han J; Zhao XG; Wang XF; Liu LY; Li ZF; Song TS; Huang C
    Cell Mol Biol (Noisy-le-grand); 2013 Nov; Suppl 59():OL1876-81. PubMed ID: 24199952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niemann-Pick type C2 protein regulates liver cancer progression via modulating ERK1/2 pathway: Clinicopathological correlations and therapeutical implications.
    Liao YJ; Fang CC; Yen CH; Hsu SM; Wang CK; Huang SF; Liang YC; Lin YY; Chu YT; Arthur Chen YM
    Int J Cancer; 2015 Sep; 137(6):1341-51. PubMed ID: 25754535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-139 regulates the proliferation and invasion of hepatocellular carcinoma through the WNT/TCF-4 pathway.
    Gu W; Li X; Wang J
    Oncol Rep; 2014 Jan; 31(1):397-404. PubMed ID: 24190507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirt6 suppresses hepatocellular carcinoma cell growth via inhibiting the extracellular signal‑regulated kinase signaling pathway.
    Zhang ZG; Qin CY
    Mol Med Rep; 2014 Mar; 9(3):882-8. PubMed ID: 24366394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue factor pathway inhibitor-2 silencing promotes hepatocellular carcinoma cell invasion in vitro.
    Zhu B; Zhang P; Zeng P; Huang Z; Dong TF; Gui YK; Zhang GW
    Anat Rec (Hoboken); 2013 Nov; 296(11):1708-16. PubMed ID: 24591127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PBK overexpression promotes metastasis of hepatocellular carcinoma via activating ETV4-uPAR signaling pathway.
    Yang QX; Zhong S; He L; Jia XJ; Tang H; Cheng ST; Ren JH; Yu HB; Zhou L; Zhou HZ; Ren F; Hu ZW; Gong R; Huang AL; Chen J
    Cancer Lett; 2019 Jun; 452():90-102. PubMed ID: 30914208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
    Nowicki TS; Zhao H; Darzynkiewicz Z; Moscatello A; Shin E; Schantz S; Tiwari RK; Geliebter J
    Cell Cycle; 2011 Jan; 10(1):100-7. PubMed ID: 21191179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroglobin, a novel intracellular hexa-coordinated globin, functions as a tumor suppressor in hepatocellular carcinoma via Raf/MAPK/Erk.
    Zhang J; Lan SJ; Liu QR; Liu JM; Chen XQ
    Mol Pharmacol; 2013 May; 83(5):1109-19. PubMed ID: 23478801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase induces stromal cell-derived factor-1 expression in human hepatocellular carcinoma cells.
    Hsu WH; Chen CN; Huang HI; Lai YL; Teng CY; Kuo WH
    J Cell Physiol; 2012 Feb; 227(2):697-704. PubMed ID: 21465475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinesin family member 2C promotes hepatocellular carcinoma growth and metastasis via activating MEK/ERK pathway.
    Ding Q; Jiang C; Zhou Y; Duan J; Lai J; Jiang M; Lin D
    Biosci Biotechnol Biochem; 2021 Oct; 85(11):2241-2249. PubMed ID: 34494081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo.
    Bessard A; Frémin C; Ezan F; Fautrel A; Gailhouste L; Baffet G
    Oncogene; 2008 Sep; 27(40):5315-25. PubMed ID: 18521085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.